Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Highlights

Selected Articles from This Issue

DOI:  Published February 2021
  • Article
  • Info & Metrics
  • PDF
Loading

Combination of AZD0364 and Selumetinib in KRAS Mutant NSCLC

Flemington et al. Page 238

Despite many clinical trials for RAS/MAp. inhibitors in various cancer indications, they remain exclusive to BRAF mutant melanoma. Targeting multiple nodes of the RAS/MAPK pathway may circumvent resistance by limiting pathway reactivation. To this end, Flemington and colleagues developed AZD0364, an ATP-competitive and highly selective inhibitor of ERK1 and ERK2. AZD0364 reduced ERK1/2 signaling markers and resulted in tumor growth inhibition in sensitive BRAF and KRAS mutant models. AZD0364 in combination with the MEK1/2 inhibitor selumetinib generated significant tumor regression in multiple KRAS xenograft models. Therefore, AZD0364 and selumetinib represent a new clinical opportunity for KRAS mutant tumors.

Sensitizing HR-proficient Pancreatic Cancer to Olaparib

Parsels et al. Page 263

Most pancreatic cancers are homologous recombination repair (HR) proficient and are therefore not sensitive to PARP inhibitor (Olaparib) monotherapy. Based on the recent clinical success of olaparib in BRCA1/2 mutant pancreatic cancer, Parsels and colleagues hypothesized radiation would synergize with olaparib in HR-proficient pancreatic cancers. Radiation was combined with olaparib and the ATR inhibitor AZD6738. Maximal radiosensitization occurred when Olaparib dosage generated PARP1-DNA complexes. The reliance of sensitization on the PARP1-DNA complex, rather than PARP catalytic activity, was confirmed through CRISPR-Cas9 deletion of PARP1. Taken together, they demonstrate combining olaparib with radiation and ATR inhibition holds promise for HR-proficient pancreatic cancers.

Auristatins with High Bystander and Cytotoxic Activity

Moquist et al. Page 320

Bystander killing by antibody-drug conjugates (ADC) may be essential in heterogeneous tumors as it targets neighboring tumor cells that do not bind the ADC itself. Auristatins with a high propensity for membrane permeabilization and bystander killing (monomethyl auristatin E, MMAE) are also susceptible to efflux pump. on multidrug-resistant (MDR) cells. Contrastingly, monomethyl auristain F (MMAF) is less susceptible to efflux pumps but is less permeable and demonstrates less bystander killing. To achieve the best of both worlds, Moquist and colleagues functionalize an MMAF scaffold to increase cell permeabilization and bystander killing. Structure-activity relationship studies demonstrate their MMAF analogues were optimized for hydrophobicity and potency in MDR+ cells.

Galunisertib and SBRT in Patients with Advanced HCC

Reiss et al. Page 389

In this manuscript, Wattenberg and colleagues lead a pilot study of the oral TGF-β inhibitor galunisertib with stereotactic body radiotherapy (SBRT) in patients with advanced hepatocellular carcinoma. Fifteen patients who progressed, refused, or were intolerant of sorafenib were treated with galunisertib for two weeks and then delivered a single dose of SBRT to lesions in the liver, lymph node, and/or lung. Exploring the differences in progressive and non-progressive patients, they found non-progressors had distinct immune cell subsets, most especially those of CD8+ T cells. Wattenberg and colleagues demonstrate galunisertib was well tolerated in the pilot study and that immune profiling could distinguish non-progression.

  • ©2021 American Association for Cancer Research.
PreviousNext
Back to top
Molecular Cancer Therapeutics: 20 (2)
February 2021
Volume 20, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Selected Articles from This Issue
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Selected Articles from This Issue
Mol Cancer Ther February 1 2021 (20) (2) 217;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Selected Articles from This Issue
Mol Cancer Ther February 1 2021 (20) (2) 217;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Combination of AZD0364 and Selumetinib in KRAS Mutant NSCLC
    • Sensitizing HR-proficient Pancreatic Cancer to Olaparib
    • Auristatins with High Bystander and Cytotoxic Activity
    • Galunisertib and SBRT in Patients with Advanced HCC
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Selected Articles from This Issue
  • Selected Articles from This Issue
Show more Highlights
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement